Ghrelin Requires p53 to Stimulate Lipid Storage in Fat and Liver

Ghrelin, a stomach-derived peptide, stimulates feeding behavior and adiposity. For its orexigenic action, ghrelin triggers a central SIRT1/p53/AMPK pathway. The tumor suppressor p53 also plays an important role in white adipose tissue (WAT), where it is up-regulated in the adipocytes of obese mice....

Full description

Saved in:
Bibliographic Details
Published inEndocrinology (Philadelphia) Vol. 154; no. 10; pp. 3671 - 3679
Main Authors Porteiro, Begoña, Díaz-Ruíz, Alberto, Martínez, Gloria, Senra, Ana, Vidal, Anxo, Serrano, Manuel, Gualillo, Oreste, López, Miguel, Malagón, María M, Diéguez, Carlos, Nogueiras, Rubén
Format Journal Article
LanguageEnglish
Published Chevy Chase, MD Endocrine Society 01.10.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Ghrelin, a stomach-derived peptide, stimulates feeding behavior and adiposity. For its orexigenic action, ghrelin triggers a central SIRT1/p53/AMPK pathway. The tumor suppressor p53 also plays an important role in white adipose tissue (WAT), where it is up-regulated in the adipocytes of obese mice. It is not known, however, whether p53 has any role in mediating the peripheral action of ghrelin. In the present study, chronic peripheral ghrelin treatment resulted in increased body weight and fat-mass gain in wild-type mice. Correspondingly, mRNA levels of several adipogenic and fat-storage-promoting enzymes were up-regulated in WAT, whereas hepatic triglyceride content and lipogenic enzymes were also increased in wild-type mice following ghrelin treatment. In contrast, mice lacking p53 failed to respond to ghrelin treatment, with their body weight, fat mass, and adipocyte and hepatic metabolism remaining unchanged. Thus, our results show that p53 is necessary for the actions of ghrelin on WAT and liver, leading to changes in expression levels of lipogenic and adipogenic genes, and modifying body weight.
Bibliography:This work has been supported by grants from Ministerio de Economia y Competitividad (C.D.: BFU2011; R.N.: RYC-2008-02219 and BFU2012-35255; A.V.: SAF2009-07389), Xunta de Galicia (M.L.: 10PXIB208164PR and R.N.: EM 2012/039; and M.M.M.: BFU2010-17116 and 2012-CP069; A.V.: EM 2012/061), Junta de Andalucía (M.M.M.: CTS-6606), Fondo Investigationes Sanitarias (M.L.: PI12/01814), Fundación Lilly (R.N.) and Fundación SEEN (R.N.), CIBER de Fisiopatología de la Obesidad y Nutrición (CIBERobn). CIBERobn is an initiative of the Instituto de Salud Carlos III (ISCIII) of Spain, which is supported by FEDER funds. The research leading to these results has also received funding from the European Community's Seventh Framework Programme under the following grants (C.D., M.L., and R.N.: FP7/2007-2013: no. 245009: NeuroFAST, and R.N.: ERC-2011-StG-OBESITY53-281408).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0013-7227
1945-7170
DOI:10.1210/en.2013-1176